File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples

TitlePrediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples
Authors
KeywordsOral cancer
Oral cavity cancer
Prognostic gene signature
HPV
P16
Issue Date2020
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/oraloncology
Citation
Oral Oncology, 2020, v. 100, p. article no. 104487 How to Cite?
AbstractObjectives: To test the performance of an oral cancer prognostic 13-gene signature for the prediction of survival of patients diagnosed with HPV-negative and p16-negative oral cavity cancer. Materials and Methods: Diagnostic formalin-fixed paraffin-embedded oral cavity cancer tumor samples were obtained from the Fred Hutchinson Cancer Research Center/University of Washington, University of Calgary, University of Michigan, University of Utah, and seven ARCAGE study centers coordinated by the International Agency of Research on Cancer. RNA from 638 Human Papillomavirus (HPV)-negative and p16-negative samples was analyzed for the 13 genes using a NanoString assay. Ridge-penalized Cox regressions were applied to samples randomly split into discovery and validation sets to build models and evaluate the performance of the 13-gene signature in predicting 2-year oral cavity cancer-specific survival overall and separately for patients with early and late stage disease. Results: Among AJCC stage I/II patients, including the 13-gene signature in the model resulted in substantial improvement in the prediction of 2-year oral cavity cancer-specific survival. For models containing age and sex with and without the 13-gene signature score, the areas under the Receiver Operating Characteristic Curve (AUC) and partial AUC were 0.700 vs. 0.537 (p < 0.001), and 0.046 vs. 0.018 (p < 0.001), respectively. Improvement in predicting prognosis for AJCC stage III/IV disease also was observed, but to a lesser extent. Conclusions: If confirmed using tumor samples from a larger number of early stage oral cavity cancer patients, the 13-gene signature may inform personalized treatment of early stage HPV-negative and p16-negative oral cavity cancer patients. Previous article in issueNext article in issue Keywords
Persistent Identifierhttp://hdl.handle.net/10722/280262
ISSN
2023 Impact Factor: 4.0
2023 SCImago Journal Rankings: 1.257
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChen, C-
dc.contributor.authorLohavanichbutr, P-
dc.contributor.authorZhang, Y-
dc.contributor.authorHouck, JR-
dc.contributor.authorUpton, MP-
dc.contributor.authorAbedi-Ardekani, B-
dc.contributor.authorAgudo, A-
dc.contributor.authorAhrens, W-
dc.contributor.authorAlemany, L-
dc.contributor.authorAnantharaman, D-
dc.contributor.authorConway, DI-
dc.contributor.authorFutran, ND-
dc.contributor.authorHolcatova, I-
dc.contributor.authorGünther, K-
dc.contributor.authorHansen, BT-
dc.contributor.authorHealy, CM-
dc.contributor.authorItani, D-
dc.contributor.authorKjaerheim, K-
dc.contributor.authorMonroe, MM-
dc.contributor.authorThomson, PJ-
dc.contributor.authorWitt, BL-
dc.contributor.authorNakoneshny, S-
dc.contributor.authorPeterson, LA-
dc.contributor.authorSchwartz, SM-
dc.contributor.authorZarins, KR-
dc.contributor.authorHashibe, M-
dc.contributor.authorBrennan, P-
dc.contributor.authorRozek, LS-
dc.contributor.authorWolf, G-
dc.contributor.authorDort, JC-
dc.contributor.authorWang, P-
dc.date.accessioned2020-01-21T11:50:54Z-
dc.date.available2020-01-21T11:50:54Z-
dc.date.issued2020-
dc.identifier.citationOral Oncology, 2020, v. 100, p. article no. 104487-
dc.identifier.issn1368-8375-
dc.identifier.urihttp://hdl.handle.net/10722/280262-
dc.description.abstractObjectives: To test the performance of an oral cancer prognostic 13-gene signature for the prediction of survival of patients diagnosed with HPV-negative and p16-negative oral cavity cancer. Materials and Methods: Diagnostic formalin-fixed paraffin-embedded oral cavity cancer tumor samples were obtained from the Fred Hutchinson Cancer Research Center/University of Washington, University of Calgary, University of Michigan, University of Utah, and seven ARCAGE study centers coordinated by the International Agency of Research on Cancer. RNA from 638 Human Papillomavirus (HPV)-negative and p16-negative samples was analyzed for the 13 genes using a NanoString assay. Ridge-penalized Cox regressions were applied to samples randomly split into discovery and validation sets to build models and evaluate the performance of the 13-gene signature in predicting 2-year oral cavity cancer-specific survival overall and separately for patients with early and late stage disease. Results: Among AJCC stage I/II patients, including the 13-gene signature in the model resulted in substantial improvement in the prediction of 2-year oral cavity cancer-specific survival. For models containing age and sex with and without the 13-gene signature score, the areas under the Receiver Operating Characteristic Curve (AUC) and partial AUC were 0.700 vs. 0.537 (p < 0.001), and 0.046 vs. 0.018 (p < 0.001), respectively. Improvement in predicting prognosis for AJCC stage III/IV disease also was observed, but to a lesser extent. Conclusions: If confirmed using tumor samples from a larger number of early stage oral cavity cancer patients, the 13-gene signature may inform personalized treatment of early stage HPV-negative and p16-negative oral cavity cancer patients. Previous article in issueNext article in issue Keywords-
dc.languageeng-
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/oraloncology-
dc.relation.ispartofOral Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectOral cancer-
dc.subjectOral cavity cancer-
dc.subjectPrognostic gene signature-
dc.subjectHPV-
dc.subjectP16-
dc.titlePrediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples-
dc.typeArticle-
dc.identifier.emailThomson, PJ: thomsonp@hku.hk-
dc.identifier.authorityThomson, PJ=rp02327-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.oraloncology.2019.104487-
dc.identifier.pmid31835136-
dc.identifier.scopuseid_2-s2.0-85076314857-
dc.identifier.hkuros308925-
dc.identifier.volume100-
dc.identifier.spagearticle no. 104487-
dc.identifier.epagearticle no. 104487-
dc.identifier.isiWOS:000507465700018-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1368-8375-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats